Nuvectis Pharma (NVCT) Cash from Financing Activities (2021 - 2026)

Nuvectis Pharma has reported Cash from Financing Activities for 6 years, with the latest figure at $7000.0 in Q1 2026.

• Quarterly Cash from Financing Activities fell 99.95% year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.6 million (down 39.4% YoY) and the FY2025 annual result came in at $29.1 million, up 149.79% from the prior year.
• Cash from Financing Activities fell to $7000.0 in Q1 2026 per NVCT's latest filing, from $166000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $15.5 million in Q1 2025 and troughed at -$578000.0 in Q2 2022.
• A 5-year average of $4.9 million and a median of $1.5 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities jumped 2386.33% in 2023, then sank 99.95% in 2026.
• Over 5 years, Cash from Financing Activities stood at -$131000.0 in 2022, then surged by 800.0% to $917000.0 in 2023, then soared by 317.56% to $3.8 million in 2024, then sank by 95.66% to $166000.0 in 2025, then tumbled by 95.78% to $7000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $7000.0, $166000.0, and $13.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.